Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

basil insulin lispro

- PMLiVE

Ipragliflozin beats diabetes rivals to Japanese approval

Astellas drug is first SGLT2 inhibitor backed by country’s regulator

- PMLiVE

Lilly agrees two antibody deals

Signs agreements with Genmab and Arteaus Therapeutics

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

- PMLiVE

Lilly: 2014 will be “most financially challenging year”

Company still to feel worst effects of patent expiries

- PMLiVE

Disney and Lilly publish diabetes books online

Digital format for resource to help families with children who have type 1 diabetes

- PMLiVE

Takeda pipeline hit by fasiglifam failure

Diabetes candidate had been set for a 2015 launch

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

- PMLiVE

First Cymbalta generics approved in the US

Lilly prepares for onslaught of competition for antidepressant

- PMLiVE

Police to probe Novo Nordisk over disclosure delay

Regulator says pharma company was late to announce FDA decision to not approve Tresiba and Ryzodeg

- PMLiVE

Study highlights poor diabetes consultation

Less than a third of patients asked for input into their treatment plans

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links